Gov. Kemp: Medical Device Manufacturer Gerresheimer Expands in Peachtree City

Atlanta, GA  – Governor Brian P. Kemp today announced that Gerresheimer, a manufacturer for the pharma and life science industry, will invest more than $88 million in expanding its manufacturing operations in Peachtree City, creating over 200 new jobs for Fayette County.

“This project is a prime example of the exciting growth of the life sciences industry in our state, with companies like Gerresheimer bringing career opportunities to all four corners of Georgia”  said Governor Brian Kemp . “Employers from across the globe can find a skilled workforce here that we are continuously investing in through innovative programs like the GEORGIA MATCH Direct College Admissions Initiative. We’re excited to see how this expansion will further benefit the community and surrounding region.”

Germany-based Gerresheimer offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems, and medical devices as well as solutions for the health and cosmetics industry. Gerresheimer currently supports more than 260 jobs in Peachtree City. The existing Gerresheimer manufacturing facility is already in the midst of an expansion, where it will support an additional 180 jobs with operations beginning in April 2024. Today’s announcement marks yet another investment by the company here in the No. 1 state for business.

“We appreciate the continuous support of the State of Georgia for our expansion in the U.S.,”  said Dietmar Siemssen, CEO of Gerresheimer AG . “The U.S. market is an important growth driver for us, and the expansion of our operations in Peachtree City will be key for growing our medical device business in the U.S. We are glad that we have found such favorable conditions and a highly motivated and skilled staff here.”

Gerresheimer’s new facility will be located in the Southpark International Industrial Park in Peachtree City, and will produce medical devices, in particular autoinjectors, to administer injectable drugs. Operations are expected to begin in fall 2024.

The company is currently hiring for various positions from entry level production employees to highly skilled engineers, quality managers, and administrative staff. Hiring for the new facility will start in early summer 2024. Interested individuals can learn more at  www.gerresheimer.com/en/careers/jobs/job-openings  or contact Vickie Britt at  Vickie.Britt@gerresheimer.com.

“We are dedicated to fostering strong partnerships and economic growth in Peachtree City, evidenced by our support of Gerresheimer’s plans to expand their facility here,”  said Peachtree City Mayor Kim Learnard . “Gerresheimer’s commitment to innovation in the pharmaceutical packaging industry aligns perfectly with our vision for a prosperous and vibrant city. We are excited about the additional employment opportunities and the positive impact this expansion will have on our community.”

“I am thrilled to witness Gerresheimer’s continued commitment to Fayette County through its expansive growth in Peachtree City. By choosing to expand in our community, they are not only creating job opportunities but also making an investment in the future,”  said Darryl A. Hicks, Chairman of the Fayette County Development Authority . “Having been an integral part of our community for three decades, Gerresheimer’s decision to grow here speaks volumes about the quality of our workforce, the strength of our local economy, and the supportive environment that Peachtree City and Fayette County provide.”

Senior Regional Project Manager Fernanda Kirchner represented the Georgia Department of Economic Development (GDEcD) Global Commerce team on this competitive project in partnership with Fayette County Development Authority, the Metro Atlanta Chamber, and Georgia Power.

“Georgia prides itself on creating long-term relationships with companies, and we have been fortunate enough to meet with Gerresheimer’s team in both Peachtree City and their headquarters in Germany multiple times,”  said GDEcD Commissioner Pat Wilson . “Companies locate in Georgia for the business friendly environment, and they choose to expand here because of the state’s solutions to the challenges facing businesses, including workforce training. Gerresheimer’s commitment to Peachtree City and Fayette County over the last 30 years shows our approach works, and we look forward to Gerresheimer’s continued growth in Georgia!”

Georgia is outpacing the nation in life sciences employment, with a 20 percent growth rate since 2015. The industry supports more than 78,000 jobs statewide, and at least 4,000 life science organizations operate in Georgia. In 2022, Georgia exported over $1 billion in medical instruments to international markets.

About Gerresheimer
Gerresheimer is an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems, and medical devices as well as solutions for the health and cosmetics industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors, and inhalers as well as vials, ampoules, tablet containers, dropper bottles, other bottles, and more. Gerresheimer ensures the safe delivery and administration of drugs to the patient. Learn more at  www.gerresheimer.com.  

UGA & Manus Among Awardees in $214M BioMADE Investment

April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

Nutrivert announces first close on $6 million Series A-2 funding round

April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.

USDOL Approves National Biomanufacturing Technician Standards

April 16, 2026
[Seattle, WA] April 15, 2026 – Apprenti, the leading national intermediary for Registered Apprenticeship (RA), is proud to announce the formal approval and filing of the National Biomanufacturing Technician Standards with the U.S. Department of Labor (USDOL). Crafted under the strategic guidance of the Apprenti Life Science Advisory Board—which includes leaders from Pfizer, Merck, Thermo Fisher, and Biogen—these standards were developed in close partnership with the Life Sciences Workforce Collaborative (LSWC) and InnovATEBIO as part of a high-impact NIIMBL project. This approval represents a foundational shift for the industry, moving away from a fragmented, state-by-state approach to a scalable, consistent model for developing biomanufacturing professionals at sites across all 50 states. The national standards provide a “plug-and-play” framework that ensures a technician trained in Massachusetts or North Carolina meets the same rigorous, industry-vetted benchmarks as one in Ohio or Missouri. The foundational development of these national standards was informed by existing Life Science RA programs from organizations across the country, including: MassBioEd, Oregon Life Sciences, National Center for Therapeutics Manufacturing (NCTM), BioSTL, Wistar Institute, North Carolina Life Sciences Apprenticeship Consortium (NCLSAC) and others. A National Engine for Talent: The filing of these standards is a cornerstone of NIIMBL’s efforts to strengthen domestic biomanufacturing capabilities and develop the workforce of the future. Beyond the standards themselves, the project is delivering a suite of resources and tools—including a comprehensive Employer Toolkit and specialized screening rubrics—that state-based organizations and employers can leverage to implement RA programming for their most in-demand roles. “These national standards set the stage for a sustainable, skills-first pipeline that mirrors the rigor of the industry’s most complex manufacturing processes,” said Daniel Weagle, Director of Life Science Business Development at Apprenti. “By providing a unified approach, we are empowering national employers to scale their workforce development efforts strategically and accessibly.” The Value Proposition of Registered Apprenticeship For Life Science employers, the Registered Apprenticeship model offers a compelling business case rooted in cost-effectiveness and long-term stability: High Retention: RA programs boast exceptional retention rates—historically as high as 89% to 90%—as apprentices are trained within a company’s specific culture and protocols from day one. Cost Efficiency: Research indicates that for every dollar spent on apprenticeship, employers see an average return of $1.47 in increased productivity and reduced recruitment costs. Inclusive Innovation: The model expands access to untapped talent pools, including non-degreed individuals and career-switchers, ensuring the biomanufacturing workforce reflects the demographics of the communities it serves. As the global biopharmaceutical market is projected to exceed $570 billion by 2032 , this partnership between Apprenti, NIIMBL, and industry leaders ensures that the U.S. workforce is not just prepared for the future of manufacturing, but is actively driving it. This project was developed with an award from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance from the U.S. Department of Commerce, National Institute of Standards and Technology (70NANB21H086). About Apprenti: Apprenti is a 501(c)(3) nonprofit organization and a U.S. Department of Labor recognized Intermediary. Apprenti designs and delivers scalable Registered Apprenticeship (RA) programs in high-demand industries. By adapting the proven apprenticeship model, Apprenti helps employers meet workforce needs while training the next generation of skilled professionals. Apprenti’s programs are industry-recognized, federally approved, and supports employers across the country. Since launching in 2015, Apprenti has partnered with employers, government agencies, and education providers to create new apprenticeship pathways. About NIIMBL The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of industry standards, and educate a world-leading workforce. Media Contact: Dan Maiese, Communications Manager, dmaiese@niimbl.org , 302-831-3824 About the Life Sciences Workforce Collaborative (LSWC) The Life Sciences Workforce Collaborative (LSWC) is a national nonprofit coalition of state, regional and national life science associations and institutes who are working together to build a competitive, and future-ready life sciences workforce. Originally founded in 2012 as the Coalition of State Bioscience Institutes (CSBI), LSWC connects industry, academia, and government partners through data-driven insights, best practice sharing, and collaborative programs. Learn more at www.LifeSciencesWorkforce.org About InnovATEBIO InnovATEBIO is a National Center for Biotechnology Education, working to advance the education of highly skilled technicians for the nation’s biotechnology workforce. Toward this goal, InnovATEBIO provides leadership in biotechnology technician education, including support for development and sharing of best practices and emerging technologies in biotechnology workforce development. Read LSWC's full announcement here.
MORE POSTS